Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based biotechnology company, on Thursday announced final data from the Phase one clinical trial of its investigational breast cancer vaccine (NCT04674306) at the 2025 San Antonio Breast Cancer Symposium (SABCS).
The trial was carried out in partnership with Cleveland Clinic and funded by a grant from the US Department of Defence.
Final Phase one results revealed that the investigational vaccine met all major primary endpoints. It was safe and well tolerated at the maximum tolerated dose (MTD), and elicited protocol-defined immune responses in 74% of participants.
Topline Phase one results indicated that all major primary endpoints were met. It assessed safety and monitored immune response to an investigational vaccine targeting alpha-lactalbumin (aLA).
Sobi agrees to acquire Arthrosi Therapeutics
Amgen's UPLIZNA receives US FDA approval
Innovent Biologics' mazdutide injection meets Phase 1b clinical study primary endpoint
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
OTR Therapeutics agrees strategic collaboration and licence agreement with Zealand Pharma A/S
Privo Technologies doses first patient in first-in-human clinical trial of PRV131
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
D3 Bio completes USD108m Series B financing round
Hemab Therapeutics announces positive Phase 2 multiple ascending dose study results for sutacimig
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
Champions Oncology expands bioanalytical services with new technology and leadership